Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa). This prevents the conversion of fibrinogen to fibrin and inhibits clot formation.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
Continuous intravenous infusion: initial bolus 80 units/kg (max 10,000 units) followed by infusion at 18 units/kg/hour (usual adult dose 1,000-2,000 units/hour). For prophylactic use: subcutaneous 5,000 units every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
Dose-dependent: 30–60 min after 25 U/kg IV, 60–90 min after 100 U/kg IV, 150 min after 400 U/kg IV. Terminal half-life: ~1.5 h (low dose) to ~5 h (high dose). Context: nonlinear due to saturable clearance mechanisms.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal (minimal, saturable) and reticuloendothelial system (heparinase). Unchanged heparin: negligible urinary excretion. Metabolites: desulfated heparin via hepatic and extrahepatic heparinase; inactive fragments cleared renally.
Category C
Category A/B
Anticoagulant
Anticoagulant